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Abstract: Cancer vaccination projects are on trial worldwide and the results are far-off being a remarkable success. Al-
beit, thousands of clinical trials are taking place, only a several of those are producing a significant result to increase the 
survival rate of the patients. Four vaccines (Human papillomavirus - HPV vaccines, Hepatitis B virus - HBV vaccines, 
Sipuleucel-T and Oncophage) are approved for market in the United States and Russia so far. Most of the prototype 
vaccines are yielding at phase III clinical trials after being successful at phase I and II. Apparently, new visions and ap-
proaches are required to guide these projects to harvest better results. 
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The idea of vaccination of a metastatic cell seemed 
like a silver bullet at first, but unfortunately not resulting 
as presumed! Recent results from clinical trials are ended 
in high deviation from the expectation to shut the possi-
bility of rapid deployment of this relatively novel thera-
py[1]. National Cancer Institute (NCI) already supported 
5465 clinical trials of different cancer vaccines[2]. Albeit, 
some of the candidates (e.g. GVAX) showed better per-
formance in phase I and II, but, the phase III clinical 
trials appeared very difficult to exceed[3]. Only two pre-
ventive vaccines have approved in the United States 
(Human papillomavirus-HPV vaccines, Hepatitis B virus 
- HBV vaccines) and one (Oncophage) has received a 
license to market in Russia[4]. Treatment vaccine against 
prostate cancer, sipuleucel-T (Provenge®) was ap-
proved by FDA in 2010. Among other vaccines, idiotype 
or immunoglobulin-based vaccine, BiovaxID failed in 
two phase III clinical trial[5]. In phase III clinical trials, 
MyVax, Favid and Biovaxid also result in a failure[6]. 
The results from MyVax concluded discovery and vali-
dation of immunologic and clinical responses biomarkers 
are critical for identifying patients more likely to 
get benefitted[7]. In phase III clinical trial, Vitespen, a 
protein-based vaccine against melanoma and advance 
renal cell carcinoma, also yielded to generate a substan-
tial survival rate[8, 9]. A similar type Gp100 was unsuc-
cessful in the reduction of tumor size[10]. The difficulty 
with peptide-based vaccines is the short and free peptides 
are likely to be discarded rapidly from the system before 
drawing an immune response. GVAX, an autologous 
whole-tumor-cell vaccine, showed no protection against 
prostate cancer in phase III clinical trials[11]. Pros-
tate-specific-antigen-targeted vaccine ProstVac is cur-
rently at phase III trials against prostate cancer, despite 
its failure to improve progression-free survival rates from 
the phase II[12, 13]. Vaccines produced from tumor-cell, 
algenpantucel-L and OncoVAX, are in Phase III clinical 
trial[14] before any conclusive decision[15, 16]. Another 
therapeutic vaccine IMA901 to cure metastatic renal cell 
carcinoma showed prolonged survival in Phase I and 
II[17], but, resulted unsuccessful to increase the survival 
rate in Phase III clinical trials[18]. So, the overall scenario 
is not very promising at this moment. 
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 Vaccination is a straight-forward solution, eliminat-
ing the excessive study of risk factors[19], but, it is also 
apparent that novel approaches are required to generate 
success for these ‘on trial’ vaccines. Other associative 
methods along with the therapeutic vaccination require 
to be designed and developed and to employ for increas-
ing the survival rate at the critical stage. Extensive study 
of biomarkers, scrutiny and analysis of the prior results 
have no alternative. Population-based personalized 
screening can also be implemented. In final words, the 
far-off dream of eradicating an enduring crisis with a 
silver bullet may take longer before displaying remarka-
ble success. 
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